{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T08:52:24Z","timestamp":1791535944339,"version":"4.3.4"},"reference-count":186,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T00:00:00Z","timestamp":1655510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T00:00:00Z","timestamp":1655510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007343","name":"Universit\u00e0 degli Studi di Brescia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007343","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Disease-specific autoantibodies are considered the most important biomarkers for systemic sclerosis (SSc), due to their ability to stratify patients with different severity and prognosis. Anti-nuclear antibodies (ANA), occurring in subjects with isolated Raynuad\u2019s phenomenon, are considered the strongest independent predictors of definite SSc and digital microvascular damage, as observed by nailfold videocapillaroscopy. ANA are present in more than 90% of SSc, but ANA negativity does not exclude SSc diagnosis: a little rate of SSc ANA negative exists and shows a distinct subtype of disease, with less vasculopathy, but more frequent lower gastrointestinal involvement and severe disease course. Anti-centromere, anti-Th\/To, and anti-Topoisomerase I antibodies could be considered as classical biomarkers, covering about 60% of SSc and defining patients with well-described cardio-pulmonary complications. In particular, anti-Topoisomerase I represent a risk factor for development of diffuse cutaneous involvement and digital ulcers in the first 3 years of disease, as well as severe interstitial lung disease (ILD). Anti-RNA polymerase III is a biomarker with new clinical implications: very rapid skin thickness progression, gastric antral vascular ectasia, the occurrence of synchronous cancers, and possible association with silicone breast implants rupture. Moreover, novel SSc specific autoantibodies have been globally described in about 10% of \u201cseronegative\u201d SSc patients: anti-elF2B, anti-RuvBL1\/2 complex, anti-U11\/U12 RNP, and anti-BICD2 depict specific SSc subtypes with severe organ complications. Many autoantibodies could be considered markers of overlap syndromes, including SSc. Anti-Ku are found in 2\u20137% of SSc, strictly defining the PM\/SSc overlap. They are associated with synovitis, joint contractures, myositis, and negatively associated with vascular manifestation of disease. Anti-U3RNP are associated with a well-defined clinical phenotype: Afro-Caribbean male patients, younger at diagnosis, and higher risk of pulmonary hypertension and gastrointestinal involvement. Anti-PM\/Scl define SSc patients with high frequency of ILD, calcinosis, dermatomyositis skin changes, and severe myositis. The accurate detection of autoantibodies SSc specific and associated with overlap syndromes is crucial for patients\u2019 stratification. ANA should be correctly identified using indirect immunofluorescent assay and a standardized way of patterns\u2019 interpretation. The gold-standard technique for autoantibodies\u2019 identification in SSc is still considered immunoprecipitation, for its high sensitivity and specificity, but other assays have been widely used in routine practice. The identification of SSc autoantibodies with high diagnostic specificity and high predictive value is mandatory for early diagnosis, a specific follow-up and the possible definition of the best therapy for every SSc subsets. In addition, the validation of novel autoantibodies is mandatory in wider cohorts in order to restrict the gap of so-called seronegative SSc patients.<\/jats:p>","DOI":"10.1007\/s12016-022-08946-w","type":"journal-article","created":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T05:02:53Z","timestamp":1655528573000},"page":"412-430","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":138,"title":["Systemic Sclerosis-Specific Antibodies: Novel and Classical Biomarkers"],"prefix":"10.1007","volume":"64","author":[{"given":"Ilaria","family":"Cavazzana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Vojinovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Airo\u2019","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micaela","family":"Fredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Ceribelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Pedretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Lazzaroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emirena","family":"Garrafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,18]]},"reference":[{"key":"8946_CR1","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.autrev.2012.05.011","volume":"12","author":"S Mehra","year":"2013","unstructured":"Mehra S, Walker J, Patterson K, Fritzler MJ (2013) Autoantibodies in systemic sclerosis. Autoimmun Rev 12:340\u2013354. https:\/\/doi.org\/10.1016\/j.autrev.2012.05.011","journal-title":"Autoimmun Rev"},{"key":"8946_CR2","unstructured":"FDA-NIH Biomarker Working Group (2016) BEST (Biomarkers, EndpointS, and other Tools) resource. Food and Drug Administration (US), Silver Spring (MD). https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK338449"},{"key":"8946_CR3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1177\/1535370217750088","volume":"243","author":"R Califf","year":"2018","unstructured":"Califf R (2018) Biomarker definitions and their applications. Exp Biol Med (Maywood) 243:213\u2013221. https:\/\/doi.org\/10.1177\/1535370217750088","journal-title":"Exp Biol Med (Maywood)"},{"key":"8946_CR4","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1001\/jama.2016.2240","volume":"315","author":"MA Robb","year":"2016","unstructured":"Robb MA, McInnes PM, Califf RM (2016) Biomarkers and surrogate endpoints: developing common terminology and definitions. JAMA 315:1107\u20131108. https:\/\/doi.org\/10.1001\/jama.2016.2240","journal-title":"JAMA"},{"key":"8946_CR5","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nrrheum.2009.238","volume":"6","author":"SI Nihtyanova","year":"2010","unstructured":"Nihtyanova SI, Denton CP (2010) Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol 6:112\u2013116. https:\/\/doi.org\/10.1038\/nrrheum.2009.238","journal-title":"Nat Rev Rheumatol"},{"key":"8946_CR6","first-page":"96","volume":"31","author":"IAFM Heijnen","year":"2013","unstructured":"Heijnen IAFM, Foocharoen C, Bannert B et al (2013) Clinical significance of coexisting antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis: a EUSTAR group-based study. Clin Exp Rheumatol 31:96\u2013102","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"8946_CR7","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1002\/art.39316","volume":"67","author":"KA Patterson","year":"2015","unstructured":"Patterson KA, Roberts-Thomson PJ, Lester S, Tan JA, Hakendorf P, Rischmueller M et al (2015) Interpretation of an extended autoantibody profile in a well-characterized australian systemic sclerosis (scleroderma) cohort using principal components analysis. Arthritis Rheumatol 67(12):3234\u20133244. https:\/\/doi.org\/10.1002\/art.39316","journal-title":"Arthritis Rheumatol"},{"key":"8946_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.semarthrit.2005.03.005","volume":"35","author":"VD Steen","year":"2005","unstructured":"Steen VD (2005) Autoantibodies in Systemic Sclerosis. Semin Arthritis Rheum 35:35\u201342","journal-title":"Semin Arthritis Rheum"},{"key":"8946_CR9","first-page":"451","volume":"56","author":"J Henes","year":"2017","unstructured":"Henes J, Glaeser L, Kotter I, Vogel W, Kanz L, Klein R (2017) Analysis of anti\u2013topoisomerase I antibodies in patients with systemic sclerosis before and after autologous stem cell transplantation. Rheumatol 56:451\u2013456","journal-title":"Rheumatol"},{"key":"8946_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0214202","volume":"14","author":"PD Burbelo","year":"2019","unstructured":"Burbelo PD, Gordon SM, Waldman M, Edison JD, Little DJ, Stitt RS et al (2019) Autoantibodies are present before the clinical diagnosis of systemic sclerosis. PLoS ONE 14:e0214202. https:\/\/doi.org\/10.1371\/journal.pone.0214202","journal-title":"PLoS ONE"},{"key":"8946_CR11","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s13075-020-02360-3","volume":"22","author":"E Raschi","year":"2020","unstructured":"Raschi E, Privitera D, Bodio C, Lonati PA, Borghi MO, Ingegnoli F et al (2020) Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis. Arthr Care Res 22:265. https:\/\/doi.org\/10.1186\/s13075-020-02360-3","journal-title":"Arthr Care Res"},{"key":"8946_CR12","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s13075-018-1689-6","volume":"20","author":"E Raschi","year":"2018","unstructured":"Raschi E, Chighizola CB, Cesana L, Privitera D, Ingegnoli F, Mastaglio F et al (2018) Immune complexes containing scleroderma-specific autoantibodies induce a profibrotic and proinflammatory phenotype in skin fibroblasts. Arthritis Res Ther 20:187. https:\/\/doi.org\/10.1186\/s13075-018-1689-6","journal-title":"Arthritis Res Ther"},{"key":"8946_CR13","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A et al (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative. Arthritis Rheum 65:2737\u20132747","journal-title":"Arthritis Rheum"},{"key":"8946_CR14","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s10165-009-0155-3","volume":"19","author":"M Satoh","year":"2009","unstructured":"Satoh M, V\u00e1zquez-Del Mercado M, Chan EK (2009) Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases. Mod Rheumatol 19:219\u2013228. https:\/\/doi.org\/10.1007\/s10165-009-0155-3","journal-title":"Mod Rheumatol"},{"key":"8946_CR15","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1002\/art.21232","volume":"52","author":"M Kuwana","year":"2005","unstructured":"Kuwana M, Okano Y, Pandey JP, Silver RM, Fertig N, Medsger TA Jr (2005) Enzyme linked immunosorbent assay for detection of anti-RNA polymerase III antibody: analytical accuracy and clinical associations in systemic sclerosis. Arthritis Rheum 52:2425\u20132432","journal-title":"Arthritis Rheum"},{"key":"8946_CR16","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1093\/rheumatology\/kep290","volume":"48","author":"T Satoh","year":"2009","unstructured":"Satoh T, Ishikawa O, Ihn H et al (2009) Clinical usefulness of anti-RNA polymerase III antibody measurement by enzyme-linked immunosorbent assay. Rheumatology 48:1570\u20131574","journal-title":"Rheumatology"},{"key":"8946_CR17","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/art.10760","volume":"48","author":"GM Mitri","year":"2003","unstructured":"Mitri GM, Lucas M, Fertig N, Steen VD, Medsger TA Jr (2003) A comparison between anti-Th\/To\u2013 and anticentromere antibody\u2013positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum 48:203\u2013209. https:\/\/doi.org\/10.1002\/art.10760","journal-title":"Arthritis Rheum"},{"key":"8946_CR18","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/art.11113","volume":"49","author":"JD Reveille","year":"2003","unstructured":"Reveille JD, Solomon SH (2003) Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthr Rheum 49:399\u2013412","journal-title":"Arthr Rheum"},{"key":"8946_CR19","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.3899\/jrheum.100316","volume":"37","author":"A Ceribelli","year":"2010","unstructured":"Ceribelli A, Cavazzana I, Franceschini F, Air\u00f2 P, Tincani A, Cattaneo R et al (2010) Anti-Th\/To are common antinucleolar autoantibodies in Italian patients with scleroderma. J Rheumatol 37:2071\u20132075. https:\/\/doi.org\/10.3899\/jrheum.100316","journal-title":"J Rheumatol"},{"key":"8946_CR20","doi-asserted-by":"publisher","first-page":"R50","DOI":"10.1186\/ar4210","volume":"15","author":"M Mahler","year":"2013","unstructured":"Mahler M, Gascon C, Patel S, Ceribelli A, Fritzler MJ, Swart A et al (2013) Rpp25 is a major target of autoantibodies to the Th\/To complex as measured by a novel chemiluminescent assay. Arthritis Res Ther 15:R50. https:\/\/doi.org\/10.1186\/ar4210","journal-title":"Arthritis Res Ther"},{"key":"8946_CR21","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.cca.2010.01.037","volume":"411","author":"D Villalta","year":"2010","unstructured":"Villalta D, Morozzi G, Tampoia M, Alpini C, Brusca I, Salgarolo V et al (2010) Antibodies to fibrillarin, PM-Scl and RNA polymerase III detected by ELISA assays in patients with systemic sclerosis. Clin Chim Acta 411:710\u2013713","journal-title":"Clin Chim Acta"},{"key":"8946_CR22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/annrheumdis-2013-203863","volume":"73","author":"N Agmon-Levin","year":"2014","unstructured":"Agmon-Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte T, Herold M et al (2014) International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis 73:17\u201323","journal-title":"Ann Rheum Dis"},{"key":"8946_CR23","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1177\/0961203316644337","volume":"25","author":"K Conrad","year":"2016","unstructured":"Conrad K, Andrade LE, Chan EK, Mahler M, Meroni PL, Pruijn GJ et al (2016) From autoantibody research to standardized diagnostic assays in the management of human diseases - report of the 12th Dresden Symposium on Autoantibodies. Lupus 25:787\u2013796","journal-title":"Lupus"},{"key":"8946_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213440","volume":"78","author":"PL Meroni","year":"2019","unstructured":"Meroni PL, Chan EK, Damoiseaux J, Andrade LEC, Bossuyt X, Conrad K et al (2019) Unending story of the indirect immunofluorescence assay on HEp-2 cells: old problems and new solutions? Ann Rheum Dis 78:e46","journal-title":"Ann Rheum Dis"},{"key":"8946_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.607541","volume":"11","author":"HW Choi","year":"2020","unstructured":"Choi HW, Kwon YJ, Park JH, Lee SY, Chun S, Won EJ et al (2020) Evaluation of a fully automated antinuclear antibody indirect immunofluorescence assay in routine use. Front Immunol 11:607541","journal-title":"Front Immunol"},{"key":"8946_CR26","doi-asserted-by":"publisher","first-page":"3904","DOI":"10.1093\/rheumatology\/keaa831","volume":"60","author":"J Irure-Ventura","year":"2021","unstructured":"Irure-Ventura J, Rodr\u00edguez C, Vergara-Prieto E, Vargas ML, Quirant B, Jurado A et al (2021) Rare immunofluorescence patterns of autoantibodies on HEp-2 cells defined by ICAP identify different autoimmune diseases in the absence of associated specificities: a Spanish multicentre study. Rheumatology 60:3904\u20133912. https:\/\/doi.org\/10.1093\/rheumatology\/keaa831","journal-title":"Rheumatology"},{"key":"8946_CR27","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1002\/art.38428","volume":"66","author":"J D\u2019Aoust","year":"2014","unstructured":"D\u2019Aoust J, Hudson M, Tatibouet S, Wick J et al (2014) Clinical and serologic correlates of anti-PM\/scl antibodies in systemic sclerosis: a multicenter study of 763 patients. Arthritis Rheum 66:1608\u20131615","journal-title":"Arthritis Rheum"},{"key":"8946_CR28","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/art.11113","volume":"49","author":"JD Reveille","year":"2003","unstructured":"Reveille JD, Solomon DH, The ACR Ad Hoc Committee on Immunologic Testing Guidelines (2003) Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Care Res 49:399\u2013412","journal-title":"Arthritis Care Res"},{"key":"8946_CR29","first-page":"1573","volume":"28","author":"EC LeRoy","year":"2001","unstructured":"LeRoy EC, Medsger TA Jr (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28:1573\u20131576","journal-title":"J Rheumatol"},{"key":"8946_CR30","doi-asserted-by":"publisher","first-page":"3902","DOI":"10.1002\/art.24038","volume":"58","author":"M Koenig","year":"2008","unstructured":"Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G et al (2008) Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud\u2019s phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 58:3902\u20133912","journal-title":"Arthritis Rheum"},{"key":"8946_CR31","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.semarthrit.2014.11.006","volume":"44","author":"GA Salazar","year":"2015","unstructured":"Salazar GA, Assassi S, Wigley F, Hummers L, Varga J, Hinchcliff M et al (2015) Antinuclear antibody-negative systemic sclerosis. Semin Arthritis Rheum 44:680\u2013686. https:\/\/doi.org\/10.1016\/j.semarthrit.2014.11.006","journal-title":"Semin Arthritis Rheum"},{"key":"8946_CR32","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/art.1780340111","volume":"34","author":"ES Weiner","year":"1991","unstructured":"Weiner ES, Hildebrandt S, Senecal JL, Daniels L, Noell S, Joyal F et al (1991) Prognostic significance of anticentromere antibodies and anti\u2013topoisomerase I antibodies in Raynaud\u2019s disease: a prospective study. Arthritis Rheum 34:68\u201377","journal-title":"Arthritis Rheum"},{"key":"8946_CR33","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.autrev.2008.06.010","volume":"7","author":"M Koenig","year":"2008","unstructured":"Koenig M, Dieude M, Senecal JL (2008) Predictive value of antinuclear antibodies: the lessons of systemic sclerosis autoantibodies. Autoimmun Rev 7:588\u2013593","journal-title":"Autoimmun Rev"},{"key":"8946_CR34","doi-asserted-by":"publisher","first-page":"4979","DOI":"10.1073\/pnas.84.14.4979","volume":"84","author":"WC Earnshaw","year":"1987","unstructured":"Earnshaw WC, Machlin PS, Bordwell BJ et al (1987) Analysis of anticentromere autoantibodies using cloned autoantigen CENP-B. Proc Natl Acad Sci USA 84:4979\u20134983","journal-title":"Proc Natl Acad Sci USA"},{"key":"8946_CR35","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.autrev.2010.09.025","volume":"10","author":"MJ Fritzler","year":"2011","unstructured":"Fritzler MJ, Rattner JB, Luft LAM et al (2011) Historical perspectives on the discovery and elucidation of autoantibodies to centromere proteins (CENP) and the emerging importance of antibodies to CENP-F. Autoimmun Rev 10:194\u2013200","journal-title":"Autoimmun Rev"},{"key":"8946_CR36","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3899\/jrheum.120264","volume":"40","author":"G Song","year":"2013","unstructured":"Song G, Hu C, Zhu H, Wang L, Zhang F, Li Y et al (2013) New centromere autoantigens identified in systemic sclerosis using centromere protein microarrays. J Rheumatol 40:461\u2013468","journal-title":"J Rheumatol"},{"key":"8946_CR37","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/B978-0-444-56378-1.00021-6","volume-title":"Autoantibodies","author":"I Cavazzana","year":"2014","unstructured":"Cavazzana I, Franceschini F (2014) Centromere antibodies. In: Shoenfeld Y, Meroni PL, Gershwin ME (eds) Autoantibodies, 3rd edn. Elsevier, pp 179\u2013184","edition":"3"},{"key":"8946_CR38","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rky002","volume":"2","author":"J Caetano","year":"2018","unstructured":"Caetano J, Nihtyanova SI, Harvey J, Denton CP, Ong VH (2018) Distinctive clinical phenotype of anti-centromere antibody-positive diffuse systemic sclerosis. Rheumatol Adv Pract 2:rky002","journal-title":"Rheumatol Adv Pract"},{"key":"8946_CR39","doi-asserted-by":"publisher","first-page":"787","DOI":"10.3899\/rheum.111133","volume":"39","author":"M Hudson","year":"2012","unstructured":"Hudson M, Mahler M, Pope J, You D et al (2012) Clinical correlates of CENP-A and CENP-B antibodies in a large cohort of patients with systemic sclerosis. J Rheumatol 39:787\u2013794","journal-title":"J Rheumatol"},{"key":"8946_CR40","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1136\/ard.2006.062901","volume":"66","author":"UA Walker","year":"2007","unstructured":"Walker UA, Tyndall A, Czirjak L et al (2007) Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 66:754\u2013763","journal-title":"Ann Rheum Dis"},{"key":"8946_CR41","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/0002-9343(80)90462-3","volume":"69","author":"MJ Fritzler","year":"1980","unstructured":"Fritzler MJ, Kinsella TD (1980) The CREST syndrome: a distinct serologic entity with anticentromere antibodies. Am J Med 69:520\u2013525","journal-title":"Am J Med"},{"key":"8946_CR42","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.semarthrit.2015.06.011","volume":"45","author":"M Hinchcliff","year":"2015","unstructured":"Hinchcliff M, Khanna S, Hsu VM et al (2015) Survival in systemic sclerosis-pulmonary arterial hypertension by serum autoantibody status in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Registry. Sem Arthr Rheum 45:309\u2013314","journal-title":"Sem Arthr Rheum"},{"key":"8946_CR43","doi-asserted-by":"publisher","first-page":"R172","DOI":"10.1186\/ar3495","volume":"13","author":"R Mierau","year":"2011","unstructured":"Mierau R, Moinzadeh P, Riemekasten G, Melchers I, Meurer M, Reichenberger F et al (2011) Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features. Arthritis Res Ther 13:R172","journal-title":"Arthritis Res Ther"},{"key":"8946_CR44","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s10067-014-2616-0","volume":"33","author":"J Gunn","year":"2014","unstructured":"Gunn J, Pauling JD, McHugh NJ (2014) Impact of anti-centromere antibodies on pulmonary function test results in patients with systemic sclerosis without established or suspected pulmonary disease. Clin Rheumatol 33:869\u2013871","journal-title":"Clin Rheumatol"},{"key":"8946_CR45","doi-asserted-by":"publisher","first-page":"10514","DOI":"10.1016\/S0021-9258(19)86738-8","volume":"254","author":"AS Douvas","year":"1979","unstructured":"Douvas AS, Achten M, Tan EM (1979) Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma. J Biol Chem 254:10514\u201310522","journal-title":"J Biol Chem"},{"key":"8946_CR46","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1126\/science.3003910","volume":"14","author":"JH Shero","year":"1986","unstructured":"Shero JH, Bordwell B, Earnshaw WC (1986) High titers of autoantibodies to topoisomerase I (Scl-70) in sera from Scleroderma patients. Science 14:737\u2013740","journal-title":"Science"},{"key":"8946_CR47","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.1073\/pnas.74.9.3800","volume":"74","author":"JJ Champoux","year":"1977","unstructured":"Champoux JJ (1977) Strand breakage by the DNA untwisting enzyme results in covalent attachment of the enzyme to DNA. Proc Natl Acad Sci USA 74:3800\u20133804","journal-title":"Proc Natl Acad Sci USA"},{"key":"8946_CR48","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S0092-8674(80)80046-8","volume":"19","author":"LF Liu","year":"1980","unstructured":"Liu LF, Liu CC, Alberts BM (1980) Type II DNA topoisomerases: enzymes that can unknot a topologically knotted DNA molecule via a reversible double-strand break. Cell 19:697\u2013707","journal-title":"Cell"},{"key":"8946_CR49","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1002\/1529-0131(199906)42:6<1179::AID-ANR14>3.0.CO;2-E","volume":"42","author":"M Kuwana","year":"1999","unstructured":"Kuwana M, Kaburaki J, Medsger TA Jr, Wright TM (1999) An immunodominant epitope on DNA topoisomerase I is conformational in nature: heterogeneity in its recognition by systemic sclerosis sera. Arthritis Rheum 42:1179\u20131188","journal-title":"Arthritis Rheum"},{"key":"8946_CR50","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1006\/excr.2000.4864","volume":"256","author":"YY Mo","year":"2000","unstructured":"Mo YY, Wang PC, Beck WT (2000) Functional expression of human DNA topoisomerase I and its subcellular localization in HeLa cells. Exp Cell Res 256:480\u2013490","journal-title":"Exp Cell Res"},{"key":"8946_CR51","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1136\/annrheumdis-2018-214436","volume":"78","author":"J Damoiseaux","year":"2019","unstructured":"Damoiseaux J, Andrade LEC, Carballo OG, Conrad K, Francescantonio PLC, Friztler M et al (2019) Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective. Ann Rheum Dis 78:879\u2013899. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214436","journal-title":"Ann Rheum Dis"},{"key":"8946_CR52","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1136\/annrheumdis-2011-200742","volume":"71","author":"FM Meier","year":"2012","unstructured":"Meier FM, Frommer KW, Dinser R, Walker UA, Czirjak L, Denton CP et al (2012) Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 71:1355\u20131360","journal-title":"Ann Rheum Dis"},{"key":"8946_CR53","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1002\/art.34482","volume":"64","author":"V Steen","year":"2012","unstructured":"Steen V, Domsic RT, Lucas M, Fertig N, Medsger TA Jr (2012) A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis. Arthritis Rheum 64:2986\u20132994","journal-title":"Arthritis Rheum"},{"key":"8946_CR54","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000008980","volume":"96","author":"ND Morgan","year":"2017","unstructured":"Morgan ND, Shah AA, Mayes MD, Domsic RT, Metsger TA Jr, Steen VD et al (2017) Clinical and serological features of systemic sclerosis in a multicenter African American cohort. Medicine (Baltimore) 96:e8980","journal-title":"Medicine (Baltimore)"},{"key":"8946_CR55","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/j.1365-2133.2007.08392.x","volume":"158","author":"Y Hamaguchi","year":"2008","unstructured":"Hamaguchi Y, Hasegawa M, Fujimoto M, Matsushita T, Komura K, Kaji K et al (2008) The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis. Br J Dermatol 158:487\u2013495. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.08392.x","journal-title":"Br J Dermatol"},{"key":"8946_CR56","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/art.1780370111","volume":"37","author":"M Kuwana","year":"1994","unstructured":"Kuwana M, Kaburaki J, Okano Y, Tojo T, Medsger TA Jr (1994) Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 37:75\u201383","journal-title":"Arthritis Rheum"},{"key":"8946_CR57","first-page":"407","volume":"24","author":"M Radi\u0107","year":"2006","unstructured":"Radi\u0107 M, Martinovi\u0107 Kaliterna D, Ljuti\u0107 D (2006) The level of anti-topoisomerase I antibodies highly correlates with metacarpophalangeal and proximal interphalangeal joints flexion contractures in patients with systemic sclerosis. Clin Exp Rheumatol 24:407\u2013412","journal-title":"Clin Exp Rheumatol"},{"key":"8946_CR58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0163894","volume":"11","author":"VK Jaeger","year":"2016","unstructured":"Jaeger VK, Wirz EG, Allanore Y et al (2016) Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study. PLoS ONE 11:e0163894","journal-title":"PLoS ONE"},{"key":"8946_CR59","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1136\/annrheumdis-2015-207271","volume":"75","author":"EG Wirz","year":"2016","unstructured":"Wirz EG, Jaeger VK, Allanore Y et al (2016) Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. Ann Rheum Dis 75:1285\u20131292","journal-title":"Ann Rheum Dis"},{"key":"8946_CR60","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/MD.0b013e31829be125","volume":"92","author":"AC Gelber","year":"2013","unstructured":"Gelber AC, Manno RL, Shah AA, Woods A, Le EN, Boin F et al (2013) Race and association with disease manifestations and mortality in scleroderma: a 20-year experience at the Johns Hopkins Scleroderma Center and review of the literature. Medicine (Baltimore) 92:191\u2013205","journal-title":"Medicine (Baltimore)"},{"key":"8946_CR61","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1093\/rheumatology\/kew298","volume":"55","author":"R Mierau","year":"2016","unstructured":"Mierau R, Kranenburg P, van den Hombergh WM, Knaapen-Hans HK, van den Hoogen FH, Fransen J, Vonk MC (2016) Survival and organ involvement in patients with limited cutaneous systemic sclerosis and anti-topoisomerase-I antibodies: determined by skin subtype or auto-antibody subtype? A long-term follow-up study. Rheumatology (Oxford) 55:2001\u20132008","journal-title":"Rheumatology (Oxford)"},{"key":"8946_CR62","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1002\/art.38390","volume":"66","author":"SI Nihtyanova","year":"2014","unstructured":"Nihtyanova SI, Schreiber BE, Ong VH et al (2014) Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthr Rheum 66:1625\u20131635","journal-title":"Arthr Rheum"},{"key":"8946_CR63","doi-asserted-by":"publisher","first-page":"R166","DOI":"10.1186\/ar3125","volume":"12","author":"S Assassi","year":"2010","unstructured":"Assassi S, Sharif R, Lasky RE et al (2010) Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthr Res Ther 12:R166. https:\/\/doi.org\/10.1186\/ar3125","journal-title":"Arthr Res Ther"},{"key":"8946_CR64","doi-asserted-by":"publisher","first-page":"R28","DOI":"10.1186\/ar2622","volume":"11","author":"K Hanke","year":"2009","unstructured":"Hanke K, Dahnrich C, Bruckner CS, Huscher D, Becker M et al (2009) Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort. Arthr Res Ther 11:R28","journal-title":"Arthr Res Ther"},{"key":"8946_CR65","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1002\/art.10977","volume":"48","author":"PQ Hu","year":"2003","unstructured":"Hu PQ, Fertig N, Medsger TA Jr, Wright TM (2003) Correlation of serum antiDNA topoisomerase I antibody levels with disease severity and disease activity in SSc. Arthritis Rheum 48:1363\u20131373","journal-title":"Arthritis Rheum"},{"key":"8946_CR66","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13075-016-0993-2","volume":"18","author":"A Fava","year":"2016","unstructured":"Fava A, Cimbro R, Wigley FM, Liu QR, Rosen A, Boin F (2016) Frequency of circulating topoisomerase-I-specific CD4 T cells predicts presence and progression of interstitial lung disease in scleroderma. Arthr Res Ther 18:99","journal-title":"Arthr Res Ther"},{"key":"8946_CR67","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1093\/rheumatology\/kez005","volume":"58","author":"M Boonstra","year":"2019","unstructured":"Boonstra M, Ninaber MK, Marsan NA, Huizinga TW, Scherer HU, de Vries-Bouwstra JK (2019) Prognostic properties of antitopoisomerase antibodies in patients identified by the ACR\/EULAR 2013 systemic sclerosis criteria [letter]. Rheumatology (Oxford) 58:730\u2013732","journal-title":"Rheumatology (Oxford)"},{"key":"8946_CR68","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1002\/art.41403","volume":"72","author":"M Boonstra","year":"2020","unstructured":"Boonstra M, Bakker JA, Grummels A et al (2020) Association of anti\u2013topoisomerase I antibodies of the IgM isotype with disease progression in anti\u2013topoisomerase I\u2013positive systemic sclerosis. Arthritis Rheum 72:1897\u20131904","journal-title":"Arthritis Rheum"},{"key":"8946_CR69","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/art.1780360405","volume":"36","author":"M Abu-Shakra","year":"1993","unstructured":"Abu-Shakra M, Guillemin F, Lee P (1993) Cancer in systemic sclerosis. Arthritis Rheum 36:460\u2013464","journal-title":"Arthritis Rheum"},{"key":"8946_CR70","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1588084","volume":"8","author":"A Watad","year":"2019","unstructured":"Watad A, McGonagle D, Bragazzi NL et al (2019) Autoantibody status in systemic sclerosis patients defines both cancer risk and survival with ANA negativity in cases with concomitant cancer having a worse survival. Oncoimmunology 8:e1588084","journal-title":"Oncoimmunology"},{"key":"8946_CR71","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/wrna.9","volume":"1","author":"S Mattijssen","year":"2010","unstructured":"Mattijssen S, Welting TJM, Pruijn GJM (2010) RNase MRP and disease. WIREs. RNA 1:102\u2013116. https:\/\/doi.org\/10.1002\/wrna.9","journal-title":"RNA"},{"key":"8946_CR72","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.1002\/art.10673","volume":"46","author":"H Van Eenennaam","year":"2002","unstructured":"Van Eenennaam H, Vogelzangs JH, Lugtenberg D, Van Den Hoogen FH, Van Venrooij WJ, Pruijn GJ (2002) Identity of the RNase MRP- and RNase P-associated Th\/To autoantigen. Arthritis Rheum 46:3266\u20133272. https:\/\/doi.org\/10.1002\/art.10673","journal-title":"Arthritis Rheum"},{"key":"8946_CR73","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.revmed.2019.12.020","volume":"41","author":"R Muller","year":"2020","unstructured":"Muller R, Benyamine A, Bertin D, Harl\u00e9 JR, Kaplanski G, Mazodier K et al (2020) Characteristics of Systemic Sclerosis patients with positive anti-Th\/To antibodies: about 6 patients and literature review. Rev Med Interne 41:440\u2013445. https:\/\/doi.org\/10.1016\/j.revmed.2019.12.020","journal-title":"Rev Med Interne"},{"key":"8946_CR74","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1136\/ard.61.9.842","volume":"61","author":"M Kuwana","year":"2002","unstructured":"Kuwana M, Kimura K, Hirakata M, Kawakami Y, Ikeda Y (2002) Differences in autoantibody response to Th\/To between systemic sclerosis and other autoimmune diseases. Ann Rheum Dis 61:842\u2013846. https:\/\/doi.org\/10.1136\/ard.61.9.842","journal-title":"Ann Rheum Dis"},{"key":"8946_CR75","doi-asserted-by":"publisher","first-page":"R78","DOI":"10.1186\/ar2276","volume":"9","author":"M Koenig","year":"2007","unstructured":"Koenig M, Fritzler MJ, Targoff IN, Troyanov Y, Sen\u00e9cal JL (2007) Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther 9:R78. https:\/\/doi.org\/10.1186\/ar2276","journal-title":"Arthritis Res Ther"},{"key":"8946_CR76","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.3899\/jrheum.131450","volume":"41","author":"M Mahler","year":"2014","unstructured":"Mahler M, Satoh M, Hudson M, Baron M, Chan JY, Chan EK, Canadian Scleroderma Research Group et al (2014) Autoantibodies to the Rpp25 component of the Th\/To complex are the most common antibodies in patients with systemic sclerosis without antibodies detectable by widely available commercial tests. J Rheumatol 41:1334\u20131343. https:\/\/doi.org\/10.3899\/jrheum.131450","journal-title":"J Rheumatol"},{"key":"8946_CR77","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/j.1756-185X.2011.01688.x","volume":"15","author":"SW Graf","year":"2012","unstructured":"Graf SW, Hakendorf P, Lester S, Patterson K, Walker JG, Smith MD et al (2012) South Australian Scleroderma Register: autoantibodies as predictive biomarkers of phenotype and outcome. Int J Rheum Dis 15:102\u2013109. https:\/\/doi.org\/10.1111\/j.1756-185X.2011.01688.x","journal-title":"Int J Rheum Dis"},{"key":"8946_CR78","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s10067-011-1751-0","volume":"30","author":"ME Krzyszczak","year":"2011","unstructured":"Krzyszczak ME, Li Y, Ross SJ, Ceribelli A, Chan EK, Bubb MR et al (2011) Gender and ethnicity differences in the prevalence of scleroderma-related autoantibodies. Clin Rheumatol 30:1333\u20131339. https:\/\/doi.org\/10.1007\/s10067-011-1751-0","journal-title":"Clin Rheumatol"},{"key":"8946_CR79","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1002\/art.1780331210","volume":"33","author":"Y Okano","year":"1990","unstructured":"Okano Y, Medsger TA Jr (1990) Autoantibody to Th ribonucleoprotein (nucleolar 7\u20132 RNA protein particle) in patients with systemic sclerosis. Arthritis Rheum 33:1822\u20131828. https:\/\/doi.org\/10.1002\/art.1780331210","journal-title":"Arthritis Rheum"},{"key":"8946_CR80","first-page":"1600","volume":"33","author":"A Fischer","year":"2006","unstructured":"Fischer A, Pfalzgraf FJ, Feghali-Bostwick CA, Wright TM, Curran-Everett D, West SG et al (2006) Anti-th\/to-positivity in a cohort of patients with idiopathic pulmonary fibrosis. J Rheumatol 33:1600\u20131605","journal-title":"J Rheumatol"},{"key":"8946_CR81","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1136\/ard.62.2.97","volume":"62","author":"V Steen","year":"2003","unstructured":"Steen V (2003) Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis 62:97\u201399. https:\/\/doi.org\/10.1136\/ard.62.2.97","journal-title":"Ann Rheum Dis"},{"key":"8946_CR82","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1172\/JCI116343","volume":"91","author":"M Kuwana","year":"1993","unstructured":"Kuwana M, Kaburaki J, Mimori T, Tojo T, Homma M (1993) Autoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis. J Clin Invest 91:1399\u20131404","journal-title":"J Clin Invest"},{"key":"8946_CR83","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.7326\/0003-4819-119-10-199311150-00007","volume":"119","author":"Y Okano","year":"1993","unstructured":"Okano Y, Steen VD, Medsger TA (1993) Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med 119:1005\u20131013","journal-title":"Ann Intern Med"},{"key":"8946_CR84","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/rheumatology\/37.1.15","volume":"37","author":"CC Bunn","year":"1998","unstructured":"Bunn CC, Denton CP, Shi-Wen X, Knight C, Black CM (1998) Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol 37:15\u201320","journal-title":"Br J Rheumatol"},{"key":"8946_CR85","doi-asserted-by":"publisher","first-page":"550","DOI":"10.3899\/jrheum.170037","volume":"44","author":"M Kuwana","year":"2017","unstructured":"Kuwana M (2017) A to-do list at diagnosis of systemic sclerosis with positive anti-RNA polymerase III antibodies. J Rheumatol 44:550\u2013552","journal-title":"J Rheumatol"},{"key":"8946_CR86","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/1529-0131(199902)42:2<275::AID-ANR9>3.0.CO;2-P","volume":"42","author":"M Kuwana","year":"1999","unstructured":"Kuwana M, Okano Y, Kaburaki J, Medsger TA Jr, Wright TM (1999) Autoantibodies to RNA polymerases recognize multiple subunits and demonstrate cross-reactivity with RNA polymerase complexes. Arthritis Rheum 42:275\u2013284","journal-title":"Arthritis Rheum"},{"key":"8946_CR87","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1002\/art.10521","volume":"46","author":"M Kuwana","year":"2002","unstructured":"Kuwana M, Kimura K, Kawakami Y (2002) Identification of an immunodominant epitope on RNA polymerase III recognized by systemic sclerosis sera: application to enzyme-linked immunosorbent assay. Arthritis Rheum 46:2742\u20132747","journal-title":"Arthritis Rheum"},{"key":"8946_CR88","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1093\/rheumatology\/ken201","volume":"47","author":"JC Parker","year":"2008","unstructured":"Parker JC, Burlingame RW, Webb TT, Bunn CC (2008) (2008) Anti-RNA polymerase III antibodies in patients with systemic sclerosis detected by indirect immunofluorescence and ELISA. Rheumatology 47:976\u2013979","journal-title":"Rheumatology"},{"key":"8946_CR89","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1177\/2397198318786158","volume":"3","author":"MG Lazzaroni","year":"2018","unstructured":"Lazzaroni MG, Air\u00f2 P (2018) Anti-RNA polymerase III antibodies in patients with suspected and definite systemic sclerosis: Why and how to screen. J Sclerod Rel Disord 3:214\u2013220","journal-title":"J Sclerod Rel Disord"},{"key":"8946_CR90","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/art.38219","volume":"66","author":"V Sobanski","year":"2014","unstructured":"Sobanski V, Dauchet L, Lef\u00e8vre G et al (2014) Prevalence of anti-RNA polymerase III antibodies in systemic sclerosis: new data from a French cohort and a systematic review and meta-analysis. Arthritis Rheumatol 66:407\u2013417","journal-title":"Arthritis Rheumatol"},{"key":"8946_CR91","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1136\/ard.2009.127621","volume":"70","author":"RT Domsic","year":"2011","unstructured":"Domsic RT, Rodriguez-Reyna T, Lucas M, Fertig N, Medsger TA Jr (2011) Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma. Ann Rheum Dis 70:104\u2013109. https:\/\/doi.org\/10.1136\/ard.2009.127621","journal-title":"Ann Rheum Dis"},{"key":"8946_CR92","doi-asserted-by":"publisher","first-page":"639","DOI":"10.3899\/jrheum.160817","volume":"44","author":"MG Lazzaroni","year":"2017","unstructured":"Lazzaroni MG, Cavazzana I, Colombo E et al (2017) Malignancies in patients with anti-RNA polymerase III antibodies and systemic sclerosis: analysis of the EUSTAR cohort and possible recommendations for screening. J Rheumatol 44:639\u2013647","journal-title":"J Rheumatol"},{"key":"8946_CR93","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.autrev.2009.02.002","volume":"8","author":"I Cavazzana","year":"2009","unstructured":"Cavazzana I, Ceribelli A, Airo\u2019 P, Zingarelli S, Tincani A, Franceschini F (2009) Anti-RNA polymerase III antibodies. A marker of systemic sclerosis with rapid onset and skin thickening progression. Autoimmun Rev 8:580\u2013584","journal-title":"Autoimmun Rev"},{"key":"8946_CR94","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1097\/BOR.0b013e3283588dcf","volume":"24","author":"VK Shanmugam","year":"2012","unstructured":"Shanmugam VK, Steen VD (2012) Renal disease in scleroderma: an update on evaluation, risk stratification, pathogenesis and management. Curr Opin Rheumatol 24:669\u2013676","journal-title":"Curr Opin Rheumatol"},{"key":"8946_CR95","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1136\/annrheumdis-2017-211912","volume":"77","author":"AL Herrick","year":"2018","unstructured":"Herrick AL, Peytrignet S, Lunt M et al (2018) Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. Ann Rheumatic Dis 77:563\u2013570. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211912","journal-title":"Ann Rheumatic Dis"},{"issue":"3","key":"8946_CR96","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s40674-016-0050-y","volume":"2","author":"RT Domsic","year":"2016","unstructured":"Domsic RT, Medsger TA Jr (2016) Autoantibodies and their role in scleroderma clinical care. Curr Treatm Opt Rheumatol 2(3):239\u2013251","journal-title":"Curr Treatm Opt Rheumatol"},{"issue":"5","key":"8946_CR97","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.3899\/jrheum.091048","volume":"37","author":"B Nguyen","year":"2010","unstructured":"Nguyen B, Assassi S, Arnett FC, Mayes MD (2010) Association of RNA polymerase III antibodies with scleroderma renal crisis. J Rheumatol 37(5):1068","journal-title":"J Rheumatol"},{"key":"8946_CR98","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1002\/art.38994","volume":"67","author":"Y Hamaguchi","year":"2015","unstructured":"Hamaguchi Y, Kodera M, Matsushita T et al (2015) Clinical and immunologic predictors of scleroderma renal crisis in Japanese systemic sclerosis patients with anti-RNA polymerase III autoantibodies. Arthritis Rhem 67:1045\u20131052","journal-title":"Arthritis Rhem"},{"key":"8946_CR99","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.3899\/jrheum.080806","volume":"36","author":"V Codullo","year":"2009","unstructured":"Codullo V, Cavazzana I, Bonino C et al (2009) Serologic profile and mortality rates of scleroderma renal crisis in Italy. J Rheumatol 36:1464\u20131469","journal-title":"J Rheumatol"},{"key":"8946_CR100","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.3899\/jrheum.100124","volume":"37","author":"A Ceribelli","year":"2010","unstructured":"Ceribelli A, Cavazzana I, Air\u00f2 P, Franceschini F (2010) Anti-RNA polymerase III antibodies as a risk marker for early gastric antral vascular ectasia (GAVE) in systemic sclerosis. J Rheumatol 37:1544","journal-title":"J Rheumatol"},{"key":"8946_CR101","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3899\/jrheum.130386","volume":"41","author":"E Ghr\u00e9nassia","year":"2014","unstructured":"Ghr\u00e9nassia E, Avouac J, Khanna D et al (2014) Prevalence, correlates and outcomes of gastric antral vascular ectasia in systemic sclerosis: a EUSTAR case-control study. J Rheumatol 41:99\u2013105","journal-title":"J Rheumatol"},{"key":"8946_CR102","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1002\/art.27549","volume":"62","author":"AA Shah","year":"2010","unstructured":"Shah AA, Rosen A, Hummers L, Wigley F, Casciola-Rosen L (2010) Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I\/III antibodies. Arthritis Rheum 62:2787\u20132795","journal-title":"Arthritis Rheum"},{"key":"8946_CR103","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.3899\/jrheum.101144","volume":"38","author":"P Air\u00f2","year":"2011","unstructured":"Air\u00f2 P, Ceribelli A, Cavazzana I, Taraborelli M, Zingarelli S, Franceschini F (2011) Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies. J Rheumatol 38:1329\u20131334","journal-title":"J Rheumatol"},{"key":"8946_CR104","doi-asserted-by":"publisher","first-page":"R211","DOI":"10.1186\/ar3544","volume":"13","author":"M Nikpour","year":"2011","unstructured":"Nikpour M, Hissaria P, Byron J et al (2011) Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. Arthritis Res Ther 13:R211","journal-title":"Arthritis Res Ther"},{"key":"8946_CR105","doi-asserted-by":"publisher","first-page":"R53","DOI":"10.1186\/ar4486","volume":"16","author":"P Moinzadeh","year":"2014","unstructured":"Moinzadeh P, Fonseca C, Hellmich M et al (2014) Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma. Arthritis Res Ther 16:R53","journal-title":"Arthritis Res Ther"},{"key":"8946_CR106","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/art.39022","volume":"67","author":"AA Shah","year":"2015","unstructured":"Shah AA, Hummers LK, Casciola-Rosen L, Visvanathan K, Rosen A, Wigley FM (2015) Examination of autoantibody status and clinical features associated with cancer risk and cancer-associated scleroderma. Arthritis Rheum 67:1053\u20131061","journal-title":"Arthritis Rheum"},{"key":"8946_CR107","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/art.38928","volume":"67","author":"AA Shah","year":"2015","unstructured":"Shah AA, Casciola-Rosen L, Rosen A (2015) Cancer-induced autoimmunity in the rheumatic diseases. Arthritis Rheum 67:317\u2013326","journal-title":"Arthritis Rheum"},{"key":"8946_CR108","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1126\/science.1246886","volume":"343","author":"CG Joseph","year":"2014","unstructured":"Joseph CG, Darrah E, Shah AA et al (2014) Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 343:152\u2013157","journal-title":"Science"},{"issue":"Suppl. 106","key":"8946_CR109","first-page":"S71","volume":"35","author":"AA Shah","year":"2017","unstructured":"Shah AA, Rosen A, Hummers LK et al (2017) Evaluation of cancer-associated myositis and scleroderma autoantibodies in breast cancer patients without rheumatic disease. Clin Exp Rheum 35(Suppl. 106):S71\u2013S74","journal-title":"Clin Exp Rheum"},{"key":"8946_CR110","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1002\/art.40893","volume":"71","author":"AA Shah","year":"2019","unstructured":"Shah AA et al (2019) Protective effect against cancer of antibodies to the large subunits of both RNA polymerases I and III in scleroderma. Arthritis Rheum 71:1571\u20131579","journal-title":"Arthritis Rheum"},{"key":"8946_CR111","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/SLA.0000000000002990","volume":"269","author":"CJ Coroneos","year":"2019","unstructured":"Coroneos CJ, Selber JC, Offodile AC II, Butler CE, Clemens MW (2019) US FDA breast implant postapproval studies. Long-term outcomes in 99,993 patients. Ann Surg 269:30\u201336","journal-title":"Ann Surg"},{"key":"8946_CR112","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/1346-8138.13292","volume":"43","author":"R Saigusa","year":"2016","unstructured":"Saigusa R, Asano Y, Nakamura K et al (2016) Association of anti-RNA polymerase III antibody and silicone breast implants in patients with systemic sclerosis. J Dermatol 43:808\u2013810","journal-title":"J Dermatol"},{"key":"8946_CR113","doi-asserted-by":"publisher","first-page":"25","DOI":"10.55563\/clinexprheumatol\/mg0paj","volume":"39","author":"MG Lazzaroni","year":"2020","unstructured":"Lazzaroni MG, Campochiaro C, Bertoldo E, De Luca G, Caimmi C, Tincani A et al (2020) Association of anti-RNA polymerase III antibody with silicone breast implants rupture in a multicenter series of Italian patients with systemic sclerosis. Clin Exp Rheumatol 39:25\u201328","journal-title":"Clin Exp Rheumatol"},{"key":"8946_CR114","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00296-017-3654-0","volume":"37","author":"F Dall\u2019Ara","year":"2017","unstructured":"Dall\u2019Ara F, Lazzaroni MG, Antonioli CM, Air\u00f2 P (2017) Systemic sclerosis with anti-RNA polymerase III positivity following silicone breast implant rupture: possible role of B-cell depletion and implant removal in the treatment. Rheumatol Int 37:847\u2013851","journal-title":"Rheumatol Int"},{"key":"8946_CR115","first-page":"465","volume":"72","author":"SI Nihtyanova","year":"2020","unstructured":"Nihtyanova SI, Sari A, Harvey JC et al (2020) Using autoantibodies and cutaneous subset to develop outcome-based disease classification in systemic sclerosis. ArthriRheum 72:465\u2013476","journal-title":"ArthriRheum"},{"key":"8946_CR116","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3899\/jrheum.160867","volume":"44","author":"AM Hoffmann-Vold","year":"2017","unstructured":"Hoffmann-Vold AM, Midtvedt O, Tennoe AH et al (2017) Cardiopulmonary disease development in anti-RNA polymerase III positive systemic sclerosis; comparative analyses from an unselected, prospective patient cohort. J Rheumatol 44:459\u2013465","journal-title":"J Rheumatol"},{"key":"8946_CR117","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1172\/JCI110295","volume":"68","author":"T Mimori","year":"1981","unstructured":"Mimori T, Akizuki M, Yamagata H, Inada S, Yoshida S, Homma M (1981) Characterization of a high molecular weight acidic nuclear protein recognized by autoantibodies in sera from patients with polymyositis-scleroderma overlap. J Clin Invest 68:611\u2013620. https:\/\/doi.org\/10.1172\/JCI110295","journal-title":"J Clin Invest"},{"key":"8946_CR118","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004713","volume":"95","author":"S Hoa","year":"2016","unstructured":"Hoa S, Hudson M, Troyanov Y, Proudman S, Walker J, Stevens W, Canadian Scleroderma Research Group (CSRG), Australian Scleroderma Interest Group (ASIG), Genetics versus Environment in Scleroderma Outcome Study (GENISOS) et al (2016) Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: clinical associations. Medicine (Baltimore) 95:e4713. https:\/\/doi.org\/10.1097\/MD.0000000000004713","journal-title":"Medicine (Baltimore)"},{"key":"8946_CR119","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-021-03801-1","author":"S Abbasi","year":"2021","unstructured":"Abbasi S, Parmar G, Kelly RD, Balasuriya N, Schild-Poulter C (2021) The Ku complex: recent advances and emerging roles outside of non-homologous end-joining. Cell Mol Life Sci. https:\/\/doi.org\/10.1007\/s00018-021-03801-1","journal-title":"Cell Mol Life Sci"},{"key":"8946_CR120","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1136\/ard.2007.073981","volume":"67","author":"B Rozman","year":"2008","unstructured":"Rozman B, Cucnik S, Sodin-Semrl S, Czirj\u00e1k L, Varj\u00fa C, Distler O et al (2008) Prevalence and clinical associations of anti-Ku antibodies in patients with systemic sclerosis: a European EUSTAR-initiated multi-centre case-control study. Ann Rheum Dis 67:1282\u20131286. https:\/\/doi.org\/10.1136\/ard.2007.073981","journal-title":"Ann Rheum Dis"},{"issue":"2 Suppl 76","key":"8946_CR121","first-page":"118","volume":"31","author":"I Cavazzana","year":"2013","unstructured":"Cavazzana I, Fredi M, Taraborelli M, Quinzanini M, Tincani A, Franceschini F (2013) A subset of systemic sclerosis but not of systemic lupus erythematosus is defined by isolated anti-Ku autoantibodies. Clin Exp Rheumatol 31(2 Suppl 76):118\u2013121","journal-title":"Clin Exp Rheumatol"},{"key":"8946_CR122","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1111\/pde.14243","volume":"37","author":"RJ Loo","year":"2020","unstructured":"Loo RJ, Nocton JJ, Harmelink MM, Chiu YE (2020) Anti-Ku antibody-positive systemic sclerosis-polymyositis overlap syndrome in an adolescent. Pediatr Dermatol 37:960\u2013961. https:\/\/doi.org\/10.1111\/pde.14243","journal-title":"Pediatr Dermatol"},{"key":"8946_CR123","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/j.1768-322x.1985.tb00387.x","volume":"54","author":"RL Ochs","year":"1985","unstructured":"Ochs RL, Lischwe MA, Spohn WH, Busch H (1985) Fibrillarin: a new protein of the nucleolus identified by autoimmune sera. Biol Cell 54:123\u2013133. https:\/\/doi.org\/10.1111\/j.1768-322x.1985.tb00387.x","journal-title":"Biol Cell"},{"key":"8946_CR124","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1002\/art.1780300709","volume":"30","author":"G Reimer","year":"1987","unstructured":"Reimer G, Pollard KM, Penning CA, Ochs RL, Lischwe MA, Busch H et al (1987) Monoclonal autoantibody from a (New Zealand black x New Zealand white) F1 mouse and some human scleroderma sera target an Mr 34,000 nucleolar protein of the U3 RNP particle. Arthritis Rheum 30:793\u2013800. https:\/\/doi.org\/10.1002\/art.1780300709","journal-title":"Arthritis Rheum"},{"key":"8946_CR125","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/art.1780350114","volume":"35","author":"Y Okano","year":"1992","unstructured":"Okano Y, Steen VD, Medsger TA Jr (1992) Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis. Arthritis Rheum 35:95\u2013100. https:\/\/doi.org\/10.1002\/art.1780350114","journal-title":"Arthritis Rheum"},{"key":"8946_CR126","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/art.24409","volume":"60","author":"R Aggarwal","year":"2009","unstructured":"Aggarwal R, Lucas M, Fertig N, Oddis CV, Medsger TA Jr (2009) Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum 60:1112\u20131118. https:\/\/doi.org\/10.1002\/art.24409","journal-title":"Arthritis Rheum"},{"key":"8946_CR127","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/sji.12510","volume":"85","author":"F Tall","year":"2017","unstructured":"Tall F, Dechomet M, Riviere S, Cottin V, Ballot E, Tiev KP et al (2017) The clinical relevance of antifibrillarin (anti-U3-RNP) autoantibodies in systemic sclerosis. Scand J Immunol 85:73\u201379. https:\/\/doi.org\/10.1111\/sji.12510","journal-title":"Scand J Immunol"},{"key":"8946_CR128","doi-asserted-by":"publisher","first-page":"799","DOI":"10.3899\/jrheum.160574","volume":"44","author":"C Mejia Otero","year":"2017","unstructured":"Mejia Otero C, Assassi S, Hudson M, Mayes MD, Estrada-Y-Martin R, Pedroza C, Canadian Scleroderma Research Group, Australian Scleroderma Cohort Study, Genetics versus Environment in Scleroderma Outcome Study et al (2017) Antifibrillarin antibodies are associated with native North American ethnicity and poorer survival in systemic sclerosis. J Rheumatol 44:799\u2013805. https:\/\/doi.org\/10.3899\/jrheum.160574","journal-title":"J Rheumatol"},{"key":"8946_CR129","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.4049\/jimmunol.139.8.2579","volume":"139","author":"JL Rodriguez-Sanchez","year":"1987","unstructured":"Rodriguez-Sanchez JL, Gelpi C, Juarez C, Hardin JA (1987) Anti-NOR 90. A new autoantibody in scleroderma that recognizes a 90-kDa component of the nucleolus-organizing region of chromatin. J Immunol 139:2579\u20132584","journal-title":"J Immunol"},{"key":"8946_CR130","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1084\/jem.174.5.1239","volume":"174","author":"EK Chan","year":"1991","unstructured":"Chan EK, Imai H, Hamel JC, Tan EM (1991) Human autoantibody to RNA polymerase I transcription factor hUBF. Molecular identity of nucleolus organizer region autoantigen NOR-90 and ribosomal RNA transcription upstream binding factor. J Exp Med 174:1239\u20131244. https:\/\/doi.org\/10.1084\/jem.174.5.1239","journal-title":"J Exp Med"},{"key":"8946_CR131","first-page":"1543","volume":"29","author":"JH Dagher","year":"2002","unstructured":"Dagher JH, Scheer U, Voit R, Grummt I, Lonzetti L, Raymond Y et al (2002) Autoantibodies to NOR 90\/hUBF: longterm clinical and serological followup in a patient with limited systemic sclerosis suggests an antigen driven immune response. J Rheumatol 29:1543\u20131547","journal-title":"J Rheumatol"},{"key":"8946_CR132","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1080\/08916934.2017.1357699","volume":"50","author":"C Liaskos","year":"2017","unstructured":"Liaskos C, Marou E, Simopoulou T, Barmakoudi M, Efthymiou G, Scheper T et al (2017) Disease-related autoantibody profile in patients with systemic sclerosis. Autoimmunity 50:414\u2013421. https:\/\/doi.org\/10.1080\/08916934.2017.1357699","journal-title":"Autoimmunity"},{"key":"8946_CR133","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.autrev.2011.03.001","volume":"10","author":"V Racanelli","year":"2011","unstructured":"Racanelli V, Prete M, Musaraj G, Dammacco F, Perosa F (2011) Autoantibodies to intracellular antigens: generation and pathogenetic role. Autoimmun Rev 10:503\u2013508","journal-title":"Autoimmun Rev"},{"key":"8946_CR134","doi-asserted-by":"crossref","unstructured":"Hudson M, Pope J, Mahler M, Tatibouet S, Steele R, Baron M et al (2012) Clinical significance of antibodies to Ro52\/TRIM21 in systemic sclerosis. Arthr Res Ther 14:R50. http:\/\/arthritis-research.com\/content\/14\/2\/R50","DOI":"10.1186\/ar3763"},{"key":"8946_CR135","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1740-2557-6-2","volume":"6","author":"JC Parker","year":"2009","unstructured":"Parker JC, Burlingame RW, Bunn CC (2009) Prevalence of antibodies to Ro-52 in a serologically defined population of patients with systemic sclerosis. J Autoimmune Dis 6:2","journal-title":"J Autoimmune Dis"},{"key":"8946_CR136","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1046\/j.1365-2249.1997.4081308.x","volume":"109","author":"SA Rutjes","year":"1997","unstructured":"Rutjes SA, Vree Egberts WT, Jongen P, Van Den Hoogen F, Pruijn GJ, Van Venrooij WJ (1997) Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin Exp Immunol 109:32\u201340","journal-title":"Clin Exp Immunol"},{"key":"8946_CR137","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.semarthrit.2011.09.008","volume":"41","author":"I Marie","year":"2012","unstructured":"Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF, Levesque H, Jouen F (2012) Short-term and long-term outcome of anti-Jo1- positive patients with anti-Ro52 antibody. Semin Arthritis Rheum 41:890\u2013899","journal-title":"Semin Arthritis Rheum"},{"key":"8946_CR138","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.autrev.2011.03.004","volume":"10","author":"P Ghillani","year":"2011","unstructured":"Ghillani P, Andre C, Toly C, Rouquette AM, Bengoufa D, Nicaise P et al (2011) Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60 kDa antibodies: results of a multicentric study. Autoimmun Rev 10:509\u2013513","journal-title":"Autoimmun Rev"},{"key":"8946_CR139","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2021.1887927","author":"AYS Lee","year":"2021","unstructured":"Lee AYS, Patterson KA, Tan DJ, Wilson ME, Proudman SM, Stevens W et al (2021) Anti-Ro52\/TRIM21 is independently associated with pulmonary arterial hypertension and mortality in a cohort of systemic sclerosis patients. Scand J Rheumatol. https:\/\/doi.org\/10.1080\/03009742.2021.1887927","journal-title":"Scand J Rheumatol"},{"key":"8946_CR140","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.autrev.2007.01.013","volume":"6","author":"M Mahler","year":"2007","unstructured":"Mahler M, Raijmakers R (2007) Novel aspects of autoantibodies to the PM\/Scl complex: clinical, genetic and diagnostic insights. Autoimmun Rev 6:432\u2013437","journal-title":"Autoimmun Rev"},{"key":"8946_CR141","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/00005792-199211000-00001","volume":"71","author":"C Marguerie","year":"1992","unstructured":"Marguerie C, Bunn CC, Copier J et al (1992) The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl. Medicine (Baltimore) 71:327\u2013336","journal-title":"Medicine (Baltimore)"},{"key":"8946_CR142","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1002\/art.1780351014","volume":"35","author":"CV Oddis","year":"1992","unstructured":"Oddis CV, Okano Y, Rudert WA et al (1992) Serum autoantibody to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations. Arthr Rheum 35:1211\u20131217","journal-title":"Arthr Rheum"},{"key":"8946_CR143","first-page":"S12","volume":"30","author":"RW Koschik","year":"2012","unstructured":"Koschik RW, Fertig N, Lucas MR et al (2012) Anti-PM-Scl antibody in patients with systemic sclerosis. Clin Exp Rheumatol 30:S12\u2013S16","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"8946_CR144","doi-asserted-by":"publisher","first-page":"R22","DOI":"10.1186\/ar2614","volume":"11","author":"K Hanke","year":"2009","unstructured":"Hanke K, Br\u00fcckner CS, D\u00e4hnrich C et al (2009) Antibodies against PM\/Scl-75 and PM\/Scl-100 are independent markers for different subsets of systemic sclerosis patients. Arthritis Res Ther 11(1):R22","journal-title":"Arthritis Res Ther"},{"key":"8946_CR145","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.semarthrit.2014.07.002","volume":"44","author":"A Guillen-Del Castillo","year":"2014","unstructured":"Guillen-Del Castillo A, Sime\u00f3n-Aznar CP, Fonollosa-Pla V et al (2014) Good outcome of interstitial lung disease in patients with scleroderma associated to anti-PM\/Scl antibody. Semin Arthritis Rheum 44:331\u2013337","journal-title":"Semin Arthritis Rheum"},{"key":"8946_CR146","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3109\/08916934.2015.1077231","volume":"48","author":"M Wodkowski","year":"2015","unstructured":"Wodkowski M, Hudson M, Proudman S et al (2015) Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects. Autoimmunity 48:542\u2013551","journal-title":"Autoimmunity"},{"issue":"23","key":"8946_CR147","doi-asserted-by":"publisher","first-page":"e2068","DOI":"10.1212\/WNL.0000000000005638","volume":"90","author":"R De Lorenzo","year":"2018","unstructured":"De Lorenzo R, Pinal-Fernandez I, Huang W et al (2018) Muscular and extramuscular clinical features of patients with anti-PM\/Scl autoantibodies. Neurology 90(23):e2068\u2013e2076","journal-title":"Neurology"},{"key":"8946_CR148","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.cca.2010.03.018","volume":"411","author":"L Maes","year":"2010","unstructured":"Maes L, Blockmans D, Verschueren P et al (2010) Anti-PM\/Scl-100 and anti-RNA-polymerase III antibodies in scleroderma. Clin Chim Acta 411:965\u2013971","journal-title":"Clin Chim Acta"},{"key":"8946_CR149","doi-asserted-by":"publisher","first-page":"5028","DOI":"10.1093\/rheumatology\/keab152","volume":"60","author":"MG Lazzaroni","year":"2021","unstructured":"Lazzaroni MG, Marasco E, Campochiaro C, DeVries-Bouwstra J, Gonzalez-Perez MI, Rojas-Serrano J et al (2021) The clinical phenotype of Systemic Sclerosis patients with anti-PM7Scl antibodies: results from the EUSTAR cohort. Rheumatology (Oxford) 60:5028\u20135041. https:\/\/doi.org\/10.1093\/rheumatology\/keab152","journal-title":"Rheumatology (Oxford)"},{"key":"8946_CR150","first-page":"303","volume":"35","author":"M Fredi","year":"2017","unstructured":"Fredi M, Bartoli F, Cavazzana I et al (2017) Calcinosis in poly-dermatomyositis: clinical and laboratory predictors and treatment options. Clin Exp Rheumatol 35:303\u2013308","journal-title":"Clin Exp Rheumatol"},{"key":"8946_CR151","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1093\/rheumatology\/kew382","volume":"56","author":"C Bruni","year":"2017","unstructured":"Bruni C, Lages A, Patel H et al (2017) Resolution of paraneoplastic PM\/Scl-positive systemic sclerosis after curative resection of a pancreatic tumour. Rheumatology (Oxford) 56:317\u2013318","journal-title":"Rheumatology (Oxford)"},{"key":"8946_CR152","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.autrev.2017.03.012","volume":"16","author":"D Bernal-Bello","year":"2017","unstructured":"Bernal-Bello D, de Tena JG, Guill\u00e9n-del Castillo A et al (2017) Novel risk factors related to cancer in scleroderma. Autoimmun Rev 16:461\u2013468","journal-title":"Autoimmun Rev"},{"key":"8946_CR153","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1042\/BJ20150828","volume":"473","author":"NC Wortham","year":"2016","unstructured":"Wortham NC, Stewart JD, Harris S, Coldwell MJ, Proud CG (2016) Stoichiometry of the eIF2B complex is maintained by mutual stabilization of subunits. Biochem J 473:571\u2013580. https:\/\/doi.org\/10.1042\/BJ20150828","journal-title":"Biochem J"},{"key":"8946_CR154","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1042\/BST20051487","volume":"33","author":"GD Pavitt","year":"2005","unstructured":"Pavitt GD (2005) eIF2B, a mediator of general and gene-specific translational control. Biochem Soc Trans 33:1487\u20131492. https:\/\/doi.org\/10.1042\/BST20051487","journal-title":"Biochem Soc Trans"},{"key":"8946_CR155","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1002\/art.39755","volume":"68","author":"ZE Betteridge","year":"2016","unstructured":"Betteridge ZE, Woodhead F, Lu H, Shaddick G, Bunn CC, Denton CP et al (2016) Brief report: anti-eukaryotic initiation factor 2B autoantibodies are associated with interstitial lung disease in patients with systemic sclerosis. Arthr Rheum 68:2778\u20132783. https:\/\/doi.org\/10.1002\/art.39755","journal-title":"Arthr Rheum"},{"key":"8946_CR156","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3109\/08923973.2011.572262","volume":"34","author":"CJ Carter","year":"2012","unstructured":"Carter CJ (2012) Epstein-Barr and other viral mimicry of autoantigens, myelin and vitamin D-related proteins and of EIF2B, the cause of vanishing white matter disease: massive mimicry of multiple sclerosis relevant proteins by the Synechococcus phage. Immunopharmacol Immunotoxicol 34:21\u201335. https:\/\/doi.org\/10.3109\/08923973.2011.572262","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"8946_CR157","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1093\/rheumatology\/kex458","volume":"57","author":"JD Pauling","year":"2018","unstructured":"Pauling JD, Salazar G, Lu H, Betteridge ZE, Assassi S, Mayes MD et al (2018) Presence of anti-eukaryotic initiation factor-2B, anti-RuvBL1\/2 and anti-synthetase antibodies in patients with anti-nuclear antibody negative systemic sclerosis. Rheumatology (Oxford) 57:712\u2013717. https:\/\/doi.org\/10.1093\/rheumatology\/kex458","journal-title":"Rheumatology (Oxford)"},{"key":"8946_CR158","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2020.100049","volume":"3","author":"A Ceribelli","year":"2020","unstructured":"Ceribelli A, Isailovic N, De Santis M, Gorlino C, Satoh M, Selmi C (2020) Autoantibodies as biomarkers for interstitial lung disease in idiopathic inflammatory myositis and systemic sclerosis: The case of anti-eIF2B antibodies. J Transl Autoimmun 3:100049. https:\/\/doi.org\/10.1016\/j.jtauto.2020.100049","journal-title":"J Transl Autoimmun"},{"key":"8946_CR159","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.chembiol.2019.12.005","volume":"27","author":"P Yenerall","year":"2020","unstructured":"Yenerall P, Das AK, Wang S, Kollipara RK, Li LS, Villalobos P et al (2020) RUVBL1\/RUVBL2 ATPase Activity Drives PAQosome Maturation, DNA Replication and Radioresistance in Lung Cancer. Cell Chem Biol 27:105\u2013121. https:\/\/doi.org\/10.1016\/j.chembiol.2019.12.005","journal-title":"Cell Chem Biol"},{"key":"8946_CR160","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.molcel.2009.05.016","volume":"34","author":"S Jha","year":"2009","unstructured":"Jha S, Dutta A (2009) RVB1\/RVB2: running rings around molecular biology. Mol Cell 34:521\u2013533. https:\/\/doi.org\/10.1016\/j.molcel.2009.05.016","journal-title":"Mol Cell"},{"key":"8946_CR161","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/acr.22163","volume":"66","author":"K Kaji","year":"2014","unstructured":"Kaji K, Fertig N, Medsger TA Jr, Satoh T, Hoshino K, Hamaguchi Y et al (2014) Autoantibodies to RuvBL1 and RuvBL2: a novel systemic sclerosis-related antibody associated with diffuse cutaneous and skeletal muscle involvement. Arthritis Care Res (Hoboken) 66:575\u2013584. https:\/\/doi.org\/10.1002\/acr.22163","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"8946_CR162","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1006\/bbrc.1998.8504","volume":"245","author":"Y Makino","year":"1998","unstructured":"Makino Y, Mimori T, Koike C, Kanemaki M, Kurokawa Y, Inoue S et al (1998) TIP49, homologous to the bacterial DNA helicase RuvB, acts as an autoantigen in human. Biochem Biophys Res Communun 245:819\u2013822. https:\/\/doi.org\/10.1006\/bbrc.1998.8504","journal-title":"Biochem Biophys Res Communun"},{"key":"8946_CR163","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1002\/art.24586","volume":"61","author":"N Fertig","year":"2009","unstructured":"Fertig N, Domsic RT, Rodriguez-Reyna T, Kuwana M, Lucas M, Medsger TA Jr et al (2009) Anti-U11\/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis. Arthritis Rheum 61:958\u2013965. https:\/\/doi.org\/10.1002\/art.24586","journal-title":"Arthritis Rheum"},{"key":"8946_CR164","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1128\/mcb.12.3.1276","volume":"12","author":"KM Wassarman","year":"1992","unstructured":"Wassarman KM, Steitz JA (1992) The low-abundance U11 and U12 small nuclear ribonucleoproteins (snRNPs) interact to form a two-snRNP complex. Mol Cell Biol 12:1276\u20131285. https:\/\/doi.org\/10.1128\/mcb.12.3.1276","journal-title":"Mol Cell Biol"},{"key":"8946_CR165","doi-asserted-by":"publisher","first-page":"6781","DOI":"10.1073\/pnas.90.14.6781","volume":"90","author":"AC Gilliam","year":"1993","unstructured":"Gilliam AC, Steitz JA (1993) Rare scleroderma autoantibodies to the U11 small nuclear ribonucleoprotein and to the trimethylguanosine cap of U small nuclear RNAs. Proc Natl Acad Sci USA 90:6781\u20136785. https:\/\/doi.org\/10.1073\/pnas.90.14.6781","journal-title":"Proc Natl Acad Sci USA"},{"key":"8946_CR166","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1002\/acr.23763","volume":"71","author":"ZH McMahan","year":"2019","unstructured":"McMahan ZH, Domsic RT, Zhu L, Medsger TA, Casciola-Rosen L, Shah AA (2019) Anti-RNPC-3 (U11\/U12) antibodies in systemic sclerosis in patients with moderate-to-severe gastrointestinal dysmotility. Arthritis Care Res (Hoboken) 71:1164\u20131170. https:\/\/doi.org\/10.1002\/acr.23763","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"8946_CR167","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab279","author":"ANEL Callejas-Moraga","year":"2021","unstructured":"Callejas-Moraga ANEL, Del-Castillo AG, Perurena-Prieto J, Sanz-Mart\u00ednez MT, Fonollosa-Pla V, Lorite-Gomez K et al (2021) Anti-RNPC-3 antibody predicts poor prognosis in patients with Interstitial Lung Disease associated to Systemic Sclerosis. Rheumatology (Oxford). https:\/\/doi.org\/10.1093\/rheumatology\/keab279","journal-title":"Rheumatology (Oxford)"},{"key":"8946_CR168","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/art.37969","volume":"65","author":"A Onishi","year":"2013","unstructured":"Onishi A, Sugiyama D, Kumagai S, Morinobu A (2013) Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum 65:1913\u20131921. https:\/\/doi.org\/10.1002\/art.37969","journal-title":"Arthritis Rheum"},{"key":"8946_CR169","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1002\/art.40065","volume":"69","author":"AA Shah","year":"2017","unstructured":"Shah AA, Xu G, Rosen A, Hummers LK, Wigley FM, Elledge SJ et al (2017) Brief Report: Anti-RNPC-3 antibodies as a marker of cancer-associated scleroderma. Arthritis Rheumatol 69:1306\u20131312. https:\/\/doi.org\/10.1002\/art.40065","journal-title":"Arthritis Rheumatol"},{"key":"8946_CR170","doi-asserted-by":"publisher","first-page":"6004","DOI":"10.1093\/emboj\/cdg592","volume":"22","author":"CC Hoogenraad","year":"2003","unstructured":"Hoogenraad CC, Wulf P, Schiefermeier N, Stepanova T, Galjart N, Small JV et al (2003) Bicaudal D induces selective dynein-mediated microtubule minus end-directed transport. EMBO J 22:6004\u20136015. https:\/\/doi.org\/10.1093\/emboj\/cdg592","journal-title":"EMBO J"},{"key":"8946_CR171","doi-asserted-by":"publisher","first-page":"E10707","DOI":"10.1073\/pnas.1712033114","volume":"114","author":"A Dharan","year":"2017","unstructured":"Dharan A, Opp S, Abdel-Rahim O, Keceli SK, Imam S, Diaz-Griffero F et al (2017) Bicaudal D2 facilitates the cytoplasmic trafficking and nuclear import of HIV-1 genomes during infection. Proc Natl Acad Sci USA 114:E10707\u2013E10716. https:\/\/doi.org\/10.1073\/pnas.1712033114","journal-title":"Proc Natl Acad Sci USA"},{"key":"8946_CR172","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.autrev.2018.01.006","volume":"17","author":"MJ Fritzler","year":"2018","unstructured":"Fritzler MJ, Hudson M, Choi MY, Mahler M, Wang M, Bentow C, Canadian Scleroderma Research Group et al (2018) Bicaudal D2 is a novel autoantibody target in systemic sclerosis that shares a key epitope with CENP-A but has a distinct clinical phenotype. Autoimmun Rev 17:267\u2013275. https:\/\/doi.org\/10.1016\/j.autrev.2018.01.006","journal-title":"Autoimmun Rev"},{"issue":"Suppl. 10","key":"8946_CR173","first-page":"815","volume":"68","author":"J Schulte-Pelkum","year":"2016","unstructured":"Schulte-Pelkum J, Wirtz D, Budde P, Zucht HD, Schulz-Knappe P, Schneider M et al (2016) The novel anti-BICD2 autoantibody potentially predicts a favorable disease course in SSc. Arthr Rheum 68(Suppl. 10):815","journal-title":"Arthr Rheum"},{"key":"8946_CR174","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s001090100258","volume":"79","author":"M Mahler","year":"2001","unstructured":"Mahler M, Mierau R, Schlumberger W, Bluthner M (2001) A population of autoantibodies against a centromere-associated protein a major epitope motif cross-reacts with related cryptic epitopes on other nuclear autoantigens and on the Epstein-Barr nuclear antigen 1. J Mol Med 79:722\u2013731. https:\/\/doi.org\/10.1007\/s001090100258","journal-title":"J Mol Med"},{"key":"8946_CR175","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/s1521-6616(03)00037-8","volume":"107","author":"M Mahler","year":"2003","unstructured":"Mahler M, Bl\u00fcthner M, Pollard KM (2003) Advances in B-cell epitope analysis of autoantigens in connective tissue diseases. Clin Immunol 107:65\u201379. https:\/\/doi.org\/10.1016\/s1521-6616(03)00037-8","journal-title":"Clin Immunol"},{"key":"8946_CR176","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.3899\/jrheum.190945","volume":"47","author":"EP Stern","year":"2020","unstructured":"Stern EP, Guerra SG, Chinque H, Acquaah V, Gonz\u00e1lez-Serna D, Ponticos M et al (2020) Analysis of anti-RNA polymerase III antibody-positive systemic sclerosis and altered GPATCH2L and CTNND2 expression in scleroderma renal crisis. J Rheumatol 47:1668\u20131677. https:\/\/doi.org\/10.3899\/jrheum.190945","journal-title":"J Rheumatol"},{"key":"8946_CR177","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1001\/archderm.1961.01580150005001","volume":"84","author":"DL Tuffanelli","year":"1955","unstructured":"Tuffanelli DL, Winckelmann RK (1955) Systemic scleroderma. Arch Dermatol 84:359\u2013371","journal-title":"Arch Dermatol"},{"key":"8946_CR178","first-page":"64","volume-title":"Rook\u2019s textbook of Dermatology","author":"MJD Goodfield","year":"2010","unstructured":"Goodfield MJD, Jones SK, Veale DJ (2010) The \u2018connective tissue diseases.\u2019 Rook\u2019s textbook of Dermatology, 8th edn. Wiley-Blackwell, Hoboken, New Yersey, USA, pp 64\u201378","edition":"8"},{"key":"8946_CR179","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.3389\/fimmu.2019.01487","volume":"10","author":"S Khatri","year":"2019","unstructured":"Khatri S, Torok KS, Mirizio E, Liu C, Astakhova K (2019) Autoantibodies in Morphea: An Update. Front Immunol 10:1487. https:\/\/doi.org\/10.3389\/fimmu.2019.01487","journal-title":"Front Immunol"},{"key":"8946_CR180","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1001\/jamadermatol.2013.4207","volume":"149","author":"JW Dharamsi","year":"2013","unstructured":"Dharamsi JW, Victor S, Aguwa N et al (2013) Morphea in adults and children cohort III: nested case-control study\u2013the clinical significance of autoantibodies in morphea. JAMA Dermatol 149:1159\u20131165","journal-title":"JAMA Dermatol"},{"key":"8946_CR181","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/art.1780260506","volume":"26","author":"K Takehara","year":"1983","unstructured":"Takehara K, Moroi Y, Nakabayashi Y et al (1983) Antinuclear antibodies in localized scleroderma. Arthritis Rheum 26:612\u2013616","journal-title":"Arthritis Rheum"},{"key":"8946_CR182","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/art.1780360815","volume":"36","author":"S Sato","year":"1993","unstructured":"Sato S, Ihn H, Soma Y et al (1993) Antihistone antibodies in patients with localised scleroderma. Arthritis Rheum 36:1137\u20131141","journal-title":"Arthritis Rheum"},{"key":"8946_CR183","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1111\/j.1365-2133.2004.06256.x","volume":"151","author":"S Sato","year":"2004","unstructured":"Sato S, Kodera M, Hasegawa M et al (2004) Antinucleosome antibody is a major autoantibody in localized scleroderma. Br J Dermatol 151:1182\u20131188","journal-title":"Br J Dermatol"},{"key":"8946_CR184","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1002\/art.21264","volume":"52","author":"F Zulian","year":"2005","unstructured":"Zulian F, Vallongo C, Woo P, Russo R, Ruperto N, Harper J et al (2005) Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum 52:2873\u20132881","journal-title":"Arthritis Rheum"},{"key":"8946_CR185","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1111\/bjd.17312","volume":"180","author":"KL Kurzinski","year":"2019","unstructured":"Kurzinski KL, Zigler CK, Torok KS (2019) Prediction of disease relapse in a cohort of paediatric patients with localized scleroderma. Br J Dermatol 180:1183\u20131189","journal-title":"Br J Dermatol"},{"key":"8946_CR186","doi-asserted-by":"publisher","first-page":"437","DOI":"10.21037\/atm-20-6222","volume":"9","author":"L Abbas","year":"2021","unstructured":"Abbas L, Joseph A, Kunzler E, Jacobe HT (2021) Morphea: progress to date and the road ahead. Ann Transl Med 9:437. https:\/\/doi.org\/10.21037\/atm-20-6222","journal-title":"Ann Transl Med"}],"container-title":["Clinical Reviews in Allergy &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-022-08946-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-022-08946-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-022-08946-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T04:15:38Z","timestamp":1683692138000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-022-08946-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,18]]},"references-count":186,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["8946"],"URL":"https:\/\/doi.org\/10.1007\/s12016-022-08946-w","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,18]]},"assertion":[{"value":"18 November 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable (review).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate and Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}